Pre-clinical Pipeline

iTeos continues to progress research programs focused on additional targets that address pathways of immunosuppression and complement the mechanism of action of the A2AR and TIGIT programs. iTeos has nominated an additional candidate targeting a new mechanism in the adenosine pathway for Investigational New Drug-enabling studies.